We describe a rare case of terminal ileal diverticulitis in a 68-year-old female with a day of history of right lower quadrant pain and tenderness, mimicking acute appendicitis. Ultrasonography revealed small sac-like out-pouching lesions with increased echogenicity of surrounding fat in thickened terminal ileum, suggesting inflamed diverticula. We diagnosed terminal ileal diverticulitis primarily by ultrasonography. The diagnosis was confirmed by subsequent computed tomography.
21 January 2025 in Journal of Vascular and Interventional Radiology
To evaluate the efficacy and safety of a novel drug-coated balloon (DCB), Genoss DCB (Genoss) using shellac plus vitamin E as an excipient, compared to a reference DCB using urea. Patients with femoropopliteal arterial disease under Rutherford classes 2-5 were enrolled in this prospective, multicenter, non-inferiority clinical trial, and randomly assigned 1:1 to Genoss DCB and IN.PACT Admiral (Medtronic). The primary endpoint was late lumen loss at 6 months, which was evaluated using CT angiography by an independent investigator blinded to the treatment assignment. A total of 119 patients from 10 institutions in the Republic of Korea were assigned to the Genoss DCB (N = 59) and IN.PACT Admiral (N = 60) groups. The late lumen loss was -0.08 ± 0.59 mm in the Genoss DCB group and 0.02 ± 0.72 mm in the IN.PACT Admiral group (P = 0.469). The upper limit of the one-sided 97.5% confidence interval for differences in late lumen loss was 0.17 mm, lower than the non-inferiority limit of 0.50 mm, demonstrating the non-inferiority of Genoss DCB as compared to IN.PACT Admiral. In addition, the two groups showed no significant differences in clinically driven target lesion revascularization, major amputation, and all-cause mortality. In this prospective, randomized trial, the safety and 6-month late lumen loss of a new DCB using shellac plus vitamin E as excipients was non-inferior compared with the reference DCB using urea as the excipient.
1 January 2024 in Journal of the Korean Society of Radiology
This study investigates the usefulness of antegrade variceal embolization using sclerosant foam to evaluate technical success and clinical outcomes in cases of hypertensive variceal bleeding. A total of 16 patients underwent percutaneous antegrade variceal embolization using foam sclerotherapy from August 2019 to January 2022. Among the patients, 12 cases were of gastroesophageal varices, two were rectal varices, and one case each was duodenal and jejunal varices, respectively. Sodium tetradecyl sulfate (STS) foam was used as a detergent for variceal bleeding sclerotherapy at various anatomical locations. The detergent was used in a foam form to promote clinical outcomes and enable the effective embolization of the entire blood vessel wall, including the ventral side, against gravity. Furthermore, STS foam could be used to help sufficiently deliver the drug to distal segments. A balloon catheter was also used to block the antegrade flow and prevent the dilution of the sclerosant. Technical success was defined as the completion of sclerotherapy for variceal bleeding as planned before the procedure to achieve the disappearance of variceal bleeding. Clinical success was defined as the complete obliteration of varices without recurrent bleeding during the follow-up period after the procedure. Technical success was 81.3%, and clinical success was 84.6%. Additionally, 15/16 of the procedures were emergencies, and there were no complications related to the procedure. Antegrade foam sclerotherapy using 3% STS for variceal bleeding is clinically safe and effective. Moreover, antegrade foam sclerotherapy can be a useful treatment option for patients with active variceal bleeding in emergency cases.
1 October 2022 in International Journal of Gastrointestinal Intervention
Gastrocutaneous fistula is a rare complication of gastric surgery and difficult to manage. Because only 6% of cases close spontaneously, surgical or endoscopic repair is usually required. However, in older patients who are often ineligible for aggressive treatment, more conservative treatment op-tions are needed. Herein, we report a case of a chronic gastrocutaneous fistula secondary to distal gastrectomy with Roux-en-Y gastrojejunostomy performed 5 years prior that was managed with intestinal feeding tube insertion through the fistula tract.Copyright (c) 2022, Society of Gastrointestinal Intervention.
25 June 2025 in International Journal of Gastrointestinal Intervention